SCHEMBL691503

SCHEMBL691503

Cc1cccc(/C=C/C(=O)O)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
NFKB1 P19838 1/20 0.53
CA4 P22748 1/20 0.53
PTGER3 P43115 8/20 0.52
PTGER2 P43116 8/20 0.52
PTGER4 P35408 7/20 0.52
PTGER1 P34995 4/20 0.52
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 1/20 0.46
HDAC3 O15379 1/20 0.45
TNKS O95271 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL690917 1.00 CA1 (0.53) CA1CA2NFKB1CA4PTGER3
SCHEMBL30560916 1.00 CA1 (0.53) CA1CA2NFKB1CA4PTGER3
SCHEMBL10589353 0.85 NFKB1 (0.69) CA1CA2NFKB1CA4PTGER3
SCHEMBL3811894 0.84 PTGER3 (0.50) CA1CA2NFKB1CA4PTGER3
SCHEMBL3811892 0.84 PTGER3 (0.50) CA1CA2NFKB1CA4PTGER3
SCHEMBL78556 0.84 CA1 (0.62) CA1CA2NFKB1CA4PTGER3
SCHEMBL2425317 0.84 CA1 (0.62) CA1CA2NFKB1CA4PTGER3
SCHEMBL78555 0.84 CA1 (0.62) CA1CA2NFKB1CA4PTGER3
SCHEMBL29386378 0.84 CA1 (0.62) CA1CA2NFKB1CA4PTGER3
SCHEMBL11830587 0.83 PTGER3 (0.71) CA1CA2NFKB1CA4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025081932-A1 RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 深圳市护家科技有限公司 2025-04-24 WO claimed
EP-2268614-B1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO KK (JP) 2013-05-15 EP claimed
US-8258340-B2 Method for producing β-mercapto carboxylic acids SHOWA DENKO K.K. (JP) 2012-09-04 US claimed
US-20110015436-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2011-01-20 US claimed
EP-2268614-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS Showa Denko K.K. (JP) 2011-01-05 EP claimed
WO-2009113711-A1 METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2009-09-17 WO claimed
WO-2025081932-A1 RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 深圳市护家科技有限公司 2025-04-24 WO disclosed
CN-116768792-B Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2024-10-18 CN disclosed
CN-116768792-A Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2023-09-19 CN disclosed
EP-2688554-A2 OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES Cevc, Gregor (DE) 2014-01-29 EP disclosed
US-20140017302-A1 OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES CEVC GREGOR (DE) 2014-01-16 US disclosed
EP-2268614-B1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO KK (JP) 2013-05-15 EP disclosed
WO-2012126966-A2 OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES CEVC GREGOR (DE) 2012-09-27 WO disclosed
WO-2009113711-A1 METHOD FOR PRODUCING -MERCAPTO CARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2009-09-17 WO disclosed
WO-2009038232-A2 METHOD FOR PRODUCING BETA-MERCAPTOCARBOXYLIC ACIDS SHOWA DENKO K.K. (JP) 2009-03-26 WO disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed
EP-1100495-A4 PROPENAMIDES AS CCR5 MODULATORS SMITHKLINE BEECHAM CORP (US) 2002-09-25 EP disclosed
EP-1100495-A1 PROPENAMIDES AS CCR5 MODULATORS SMITHKLINE BEECHAM CORPORATION (US) 2001-05-23 EP disclosed
WO-2000006153-A1 PROPENAMIDES AS CCR5 MODULATORS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140017302-A1 OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES CD68, CHMP4B, ANXA5 CA1 3438/4885CA2 2151/4885NFKB1 2639/4885
US-20110015436-A1 METHOD FOR PRODUCING BETA-MERCAPTO CARBOXYLIC ACIDS CBS, ALDH7A1, CBR1 CA1 349/4885CA2 665/4885NFKB1 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.